Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 11, 2015, Pages 1999-2003

  Seaman, C D ^a,b   Yabes, J ^a   Comer, D M ^a   Ragni, M V ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Hemophilia Center of Western Pennsylvania   (United States)

Author keywords

Cardiovascular disease; Thrombosis; Von Willebrand disease; Von Willebrand factor; Von Willebrand factor deficiency

Indexed keywords

VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HEMOSTASIS; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REGISTER; RISK FACTOR; SHEAR STRESS; SMOKING; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE; AGED; BLOOD; CARDIOVASCULAR DISEASES; DISEASE RESISTANCE; GENETIC PREDISPOSITION; GENETICS; HYPERLIPIDEMIAS; MIDDLE AGED; PHYSIOLOGY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES; VON WILLEBRAND DISEASES;

ADULT; AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DISEASE RESISTANCE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OBESITY; PATIENT DISCHARGE; PREVALENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; UNITED STATES; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84946615749     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13142     Document Type: Article

References (20)

1. Paulinska P, Spiel A, Jilma B. Role of von Willebrand in vascular disease. Hamostaseologie 2009; 29: 32-8.
2. Sonneveld MAH, de Maat MPM, Leebeek FWG. von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev 2014; 28: 167-78.
3. Nichols WL. The Diagnosis, Evaluation, and Management of von Willebrand Disease. Bethesda, MD: National Heart, Lung, and Blood Institute. NIH Pub. No. 08-5832. 2007.
4. Fuster V, Bowie EJ, Lewis JC, Fass DN, Owen CA, Brown AL. Resistance to arteriosclerosis in pigs with von Willebrand's disease. Spontaneous and high cholesterol diet-induced arteriosclerosis. J Clin Invest 1978; 61: 722-730.
5. Fuster V, Fass DN, Kaye MP, Josa M, Zinsmeister AR, Bowie EJ. Arteriosclerosis in normal and von Willebrand pigs: long-term prospective study and aortic transplantation study. Circ Res 1982; 51: 587-93.
6. Badimon L, Steele P, Badimon JJ, Bowie EJ, Fuster V. Aortic atherosclerosis in pigs with heterozygous von Willebrand disease. Comparison with homozygous von Willebrand and normal pigs. Arteriosclerosis 1985; 5: 366-70.
7. Griggs TR, Reddick RL, Sultzer D, Brinkhous KM. Susceptibility to atherosclerosis in aortas and coronary arteries of swine with von Willebrand's disease. Am J Pathol 1981; 102: 137-45.
8. Bilora F, Dei RC, Girolami B, Casonato A, Zanon E, Bertomoro A, Girolami A. Do hemophilia A and von Willebrand disease protect against carotid atherosclerosis? A comparative study between coagulopathics and normal subjects by means of carotid echo-color Doppler scan. Clin Appl Thromb Hemost 1999; 5: 232-5.
9. Bilora F, Boccioletti V, Zanon E, Petrobelli F, Girolami A. Hemophilia A, von Willebrand disease, and atherosclerosis of abdominal aorta and leg arteries: factor VIII and von Willebrand factor defects appear to protect abdominal aorta and leg arteries from atherosclerosis. Clin Appl Thromb Hemost 2001; 7: 311-13.
10. Sramek A, Reiber JH, Gerrits WB, Rosendaal FR. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation 2001; 104: 762-7.
11. Sanders YV, Eikennboom J, De Wee EM, van der Bom JG, Cnossen MH, Degenaar-Dujardin ME, Fijnvandraat K, Kamphuisen PW, Laros-van Gorkom BA, Meijer K, Mauser-Bunschoten EP, Leebeek FW. Reduced prevalence of arterial thrombosis in von Willebrand disease. J Thromb Haemost 2013; 11: 845-54.
12. HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2011. Rockville, MD: Agency for Healthcare Research and Quality. www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed 15 September 2014.
13. Classifications of Diseases, Functioning, and Disability. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Hyattsville, MD: National Center for Health Statistics. http://www.cdc.gov/nchs/icd/icd9cm.html. Accessed 7 July 2014.
14. von Drygalski A, Kolaitis NA, Bettencourt R, Bergstrom J, Kruse-Jarres R, Quon DV, Wassel C, Li MC, Waalen J, Elias DJ, Mosnier LO, Allison M. Prevalence and risk factors for hypertension in hemophilia. Hypertension 2013; 62: 209-15.
15. Pocoski J, Ma A, Kessler CM, Boklages S, Humphries TJ. Cardiovascular comorbidities are increased in US patients with haemophilia A: a retrospective database analysis. Haemophilia 2014; 20: 472-8.
16. Fransen van de Putte DE, Fischer K, Makris M, Tait RC, Chowdary P, Collins PW, Meijer K, Roosendaal G, Schutgens REG, Mauser-Bunschoten EP. Unfavourable cardiovascular disease risk profiles in a cohort of Dutch and British haemophilia patients. Thromb Haemost 2013; 109: 16-23.
17. Biere-Rafi S, Baarslag MA, Peters M, Kruip MJHA, Kraaijenhagen RA, Den Heijer M, Buller HR, Kamphuisen PW. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105: 274-8.
18. Burns EM, Rigby E, Mamidanna R, Bottle A, Aylin P, Ziprin P, Faiz OD. Systematic review of discharge coding accuracy. J Public Health 2011; 34: 138-48.
19. Davies MJ. The pathophysiology of acute chest syndromes. Heart 2000; 83: 361-6.
20. Bartunek J, Barbato E, Heyndrickx G, Vanderheyden M, Wijns W, Holz JB. Novel antiplatelet agents: ALX-0081, a nanobody directed towards von Willebrand factor. J Cardiovasc Transl Res 2013; 6: 355-63.